The retrospective study carried out at Karolinska University Hospital in Sweden describes the clinical outcome of 50 patients who underwent cranioplasty with a total 53 OSSDSIGN® Cranial implants. 64% of the patients had experienced previous implant failures with other treatment options (autologous bone and/or alloplastic materials). 40 % of the patients had previous problems with infections, which is one of the most common complications leading to implant failure and subsequent explantation in cranioplasty.
In this patient cohort the explantation rate due to early post-operative infection for OSSDSIGN® Cranial was 1.9% (1/53) at a median follow-up time of 25 months. The explanted patient was successfully re-implanted with OSSDSIGN® Cranial without any signs of complications at the 6-month post-op follow-up. The publication concludes that OSSDSIGN® Cranial appears to have improved the clinical outcome, and particularly notes the regenerative effect of the implant as an important factor in achieving successful long-term outcome.